We are proud to introduce a distinctive offering in the compounding industry. Our formula features a concentration of 5mg/mL, as opposed to the more common 3mg/mL, which allows for a reduced volume to be held under the tongue. Additionally, we are providing a gel formulation rather than a liquid. This choice enhances ease of dosing, eliminates the need for messy syringes, and allows for a significantly extended absorption time for transmucosal delivery.
Semaglutide Sublingual Gel is a compounded formulation prepared by HDRx according to individualized prescriber specifications, including customized concentration and dispensing format. A valid prescription from a licensed healthcare provider is required.
Semaglutide is a GLP-1 receptor agonist that may be incorporated into provider-directed metabolic care plans when clinically appropriate. A sublingual gel formulation allows placement under the tongue as directed by the prescribing professional.
Compounding enables healthcare providers to tailor concentration and dosage form based on individualized monitoring preferences and clinical considerations.
HDRx collaborates with healthcare providers to support individualized metabolic care planning through customized medication preparation and coordination with medical professionals. Learn more about related services on our Weight Management page.
Compounded medications are not FDA-approved and are prepared to meet specific patient needs. Patients should consult their licensed healthcare provider to determine whether this formulation is appropriate for their individual care plan.
Sublingual formulations have become a preferred route for many medications with poor gastrointestinal absorption or first-pass metabolism challenges — and semaglutide is no exception. Our gel is compounded in an accredited facility and sourced from FDA-registered suppliers, ensuring prescribers have a safe, high-quality option to offer patients who are either unable or unwilling to use injectables.Â
